TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Interstitial Cystitis Problem (ICPI) Index Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transdermal Alcohol Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Oxford scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rate based on disease imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Narcolepsy Severity Scale (NSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean arterial pressure (MAP) <60 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: concentration of tramadol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-transplant relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: risk of cervical intraepithelial neoplasia (CIN) 2 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Satisfaction rate of sedation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of major clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac or cerebrovascular event (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Pain Pressure Threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Response Criteria for the Composite Endpoint of ALP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver biochemistry outcomes
Primary endpoint: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Shift of ≥ 2 CTCAE Grades From Baseline in Treatment-emergent Laboratory Abnormalities Related to Hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: frequency of repeat lumpectomy
Endpoint domain: Adverse events/effects
Primary endpoint: Time to normalization of temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peds-QL-gastro
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LEN Plasma concentration at the End of the Dosing Interval (Week 26)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LEN Plasma concentration at the End of the Dosing Interval (Week 52)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional Assessment of Cancer Therapy - General
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Numeric Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure Of Victim Empowerment Related to Safety (MOVERS) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients persisting on insulin glargine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Positive predictive value of the device in determining infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants who enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who adhered to session attendance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cognitive Function Improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Memory Improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: amount of fibrillar and oligomeric amyloid peptide and phosphorylated tau protein in stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DSME/S uptake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DSME/S retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: meperidine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Power output during sprint testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left ventricular end-systolic volume (LVESV) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in left ventricular end-diastolic volume (LVEDV) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perfusion of native kidneys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cognitive dual-task interference (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical dual-task interference (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional pelvic pain scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Achieving target AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: collagen density content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin surface topography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of phage therapy + DAIR
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of phage therapy + DAIR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ecchymosis Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort Measurement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Rhodes Index of Nausea, Vomiting, and Retching
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short-Form McGill Pain Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insomnia Severity Index Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reliability and interpretability of exposure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: likelihood of suicidal behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Tetanus-diptheria specific IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number and types of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PSQI total scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: BOLD response
Endpoint domain: null
Endpoint subdomain: null
Primary endpoint: Changes in Verbal Learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Attention and Executive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Attention and Processing Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in Motor Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from ART cessation until meeting ART restart criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment-emergent adverse events (AEs) of grade 3 or higher related to study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: IL-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pulse rate accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb Volume - Circumferential Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of COVID-19 sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who receive the flu vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety and tolerability of CC-220 and CC-99282
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline of Respiratory Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline of oxygen saturation in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale for Spasmodic Cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale for Congestive Cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-serotype specific Shigella LPS/O-Antigen IgG GMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of infants with solicited administration site events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of infants with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PM2.5 exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BC exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary bisphenol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary phthalate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary polycyclic aromatic hydrocarbon level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary volatile organic compound level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Maximal Chorea (TMC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of overall adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Opioid use disorder at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of atrial fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LISA failure within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of augmented reality in intraoperative measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in metabolic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of resolution of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who experienced postoperative major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with cognitive assessments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Safety of Minnelide capsules
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Vaccine-related Serious AE (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Serotype Specific Opsonophagocytic (OPA) Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With ≥4-fold Change From Baseline in Serotype Specific OPA Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Maximum Voluntary Contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heat pain with vibration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Adequacy Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability Level
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cytological change after thermoablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with positive margins post-op
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: False discovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stance phase time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of metabolic syndrome (MetS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the number of MetS risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive Youth Development score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of Traumatic Brain Injury (TBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage change from baseline in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with weight loss of≥5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of dose limited toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Jak3 expression in vitiligo lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of incidence of MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consistency of disability degree
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fugal-Meyer Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Pharmacodynamic change in PBMC O-GlcNAcylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PD change in percentage of O-GlcNAcase (OGA) enzyme occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Generalized Anxiety Disorder 7-item (GAD7)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood BHB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite whole-body muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Shoulder Functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood pressure and hypertension of women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood pressure and hypertension of offspring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: level of glycosylated hemoglobin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Curve of the Receiver Operating Characteristics Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abundance of intestinal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in WOMAC Knee Osteoarthritis Index (Total Score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in inappropriate prescribing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of grade 3-4 acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of multiFiltratePRO treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual Patient Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total ultrafiltration volume from hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threshold of peanut reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of skilled delivery service utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of antenatal care service utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Unbound area under the concentration vs. time curve from zero to infinity (AUCu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound maximum observed drug concentration (Cmax,u)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease progression-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Intraoperative Warm Ischemia time (WIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal function: serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal function: estimated GFR (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Tolerated Dose/Maximum Administered Dose (MTD/MAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Median nerve fractional anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in median nerve fractional anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disposition Index (DI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-Reported Postoperative Pain During the First Week Postoperative PRK
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Self-Reported Intermediate-Term Postoperative Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Epithelial Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak oxygen uptake (peak VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of metabolic rates of glucose response pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Lead levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lung ultrasound score (LUS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Absolute flow quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of significant coronary stenoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained Complete Clinical Response for 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Difference in Scores on the Dimensional Anhedonia Rating Scale (DARS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in GPi Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Body Esteem
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in inflammatory response measured by TNF-α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of closed pockets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of subjects who experienced device/procedure related Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: delay/variability of operative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Uptake feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Satisfaction Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clearance of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient observer scar assessment score (POSAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the concentration-time curve from extrapolated to infinity (AUC 0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frontal spectral power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pain perception scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain catastrophizing scales scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the concentration-time curve of the analyte in plasma (AUC0-215h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective sleep quality (Pittsburg Sleep Quality Index)
Endpoint domain: Life impact
Endpoint subdomain: Sleep